Uprzej­mie infor­mu­je­my, że NCBiR otwo­rzył nabór wnio­sków w kon­kur­sie w ramach TRANSCAN‑3 ERA-NET. Celem ini­cja­ty­wy jest wzmoc­nie­nie współ­pra­cy mię­dzy­na­ro­do­wej w dzie­dzi­nie badań nad nowo­two­ra­mi.

Pierw­szy kon­kurs w ramach pro­gra­mu TRANSCAN‑3 (Joint Trans­na­tio­nal Call 2021) obej­mu­je finan­so­wa­nie pro­jek­tów z zakre­su nowej gene­ra­cji immu­no­te­ra­pii nowo­two­rów: Next gene­ra­tion can­cer immu­no­the­ra­py: tar­ge­ting the tumo­ur micro­envi­ron­ment.

Szcze­gó­ło­we infor­ma­cje o kon­kur­sie:

Dla kogo
Mikro­fir­ma,
Mała i śred­nia fir­ma,
Duża fir­ma,
Kon­sor­cjum,
Uczel­nia,
Jed­nost­ka nauko­wa.

Na co
Dofi­nan­so­wa­nie moż­na prze­zna­czyć na reali­za­cję badań prze­my­sło­wych i prac roz­wo­jo­wych.

Part­ne­rzy
Austria, Bel­gia, Esto­nia, Fran­cja, Hisz­pa­nia, Irlan­dia, Izra­el, Kana­da, Łotwa, Niem­cy, Nor­we­gia, Por­tu­ga­lia, Rumu­nia, Sło­wa­cja, Węgry, Wło­chy, Taj­wan, Tur­cja

Budżet kon­kur­su
1 200 000 euro na wszyst­kie pro­jek­ty z udzia­łem pol­skich part­ne­rów;
Kurs EBC z dnia otwar­cia kon­kur­su, tj. 06.04.2021 r. – 4,5914 PLN

Har­mo­no­gram kon­kur­su
Data ogło­sze­nia kon­kur­su lub ini­cja­ty­wy: 06.04.2021 r.
Roz­po­czę­cie nabo­ru wnio­sków: 06 kwiet­nia 2021 r.
Zakoń­cze­nie nabo­ru wnio­sków: 29 czerw­ca 2021 r.; godz. 12.00
Wyni­ki kon­kur­su – maj 2022
Publi­ka­cja listy ran­kin­go­wej- maj 2022

 

Spo­sób skła­da­nia wnio­sków
Nabór wnio­sków mię­dzy­na­ro­do­wych odby­wa się poprzez sys­tem elek­tro­nicz­ny, dostęp­ny od 20 kwiet­nia 2021 na mię­dzy­na­ro­do­wej stro­nie kon­kur­su: https://ptoutline.eu/app/transcan2021

W celu zło­że­nia wnio­sku pro­si­my o kon­takt z Dzia­łem Pro­jek­tów Mię­dzy­na­ro­do­wych Uni­wer­sy­te­tu Medycz­ne­go w Łodzi.

Szcze­gó­ło­we infor­ma­cje na temat kon­kur­su dostęp­ne są na stro­nie NCBi­Ru[link: https://www.gov.pl/web/ncbr/transcan-3-era-net].

Zakres tema­tycz­ny
“Next gene­ra­tion can­cer immu­no­the­ra­py: tar­ge­ting the tumo­ur micro­envi­ron­ment”

 

Despi­te advan­ces in immu­no­the­ra­pies, obstac­les and chal­len­ges, inc­lu­ding limi­ted respon­se rates, the ina­bi­li­ty to pre­dict cli­ni­cal effi­ca­cy, and poten­tial side effects such as auto­im­mu­ne reac­tions or cyto­ki­ne rele­ase syn­dro­mes, rema­in and hin­der fur­ther appli­ca­tions of immu­no­the­ra­pies in cli­nics. Thus, a deeper under­stan­ding of the TME, able to dis­sect distinct clas­ses and sub­c­las­ses of it, is essen­tial for deci­phe­ring new mecha­ni­sms of immu­no­the­ra­pies, defi­ning new pre­dic­ti­ve bio­mar­kers, and iden­ti­fy­ing novel the­ra­peu­tic tar­gets. In the con­text of trans­la­tio­nal rese­arch, this topic at the inter­sec­tion of labo­ra­to­ry and cli­ni­cal rese­arch in immu­no-onco­lo­gy will com­pri­se two gene­ral aims which con­cur to the possi­ble cli­ni­cal appli­ca­tions. Pro­po­sals will have to cover at least one of the six (6) spe­ci­fic sub-aims listed below. Appro­aches sho­uld be direc­ted to draw up a mul­ti­di­men­sio­nal TME map paving the road for new effi­ca­cio­us immu­no­the­ra­py stra­te­gies. Pro­jects sho­uld be built from a solid and esta­bli­shed hypo­the­sis and sho­uld be rele­vant with regards to the possi­ble impro­ve­ments in cli­ni­cal prac­ti­ce

Aim 1: Iden­ti­fi­ca­tion and vali­da­tion of TME sub­c­las­ses and the­ir con­tri­bu­tion to the resi­stan­ce mecha­ni­sms: Trans­la­tio­nal rese­arch using tumo­ur sam­ples col­lec­ted from retro­spec­ti­ve and/or pro­spec­ti­ve cohorts of patients.

1.1 Dis­sec­tion of tumo­ur cel­l­s/tu­mo­ur-infil­tra­ting immune/stromal cells and iden­ti­fi­ca­tion of TME sub­c­las­ses (sin­gle-cell ana­ly­ses, mass cyto­me­try, ima­ging, mul­ti­di­men­sio­nal immu­no­hi­sto­che­mi­stry, etc.) for TME stu­dies (3D cul­tu­re sys­tems; patient-deri­ved orga­no­ids; patient-deri­ved xeno­gra­fts; syn­ge­ne­ic, gene­ti­cal­ly modi­fied and che­mi­cal car­ci­no­ge­ne­sis-indu­ced mouse models, etc.).

1.2 Defi­ni­tion of the con­tri­bu­tion of TME to resi­stan­ce mecha­ni­sms and iden­ti­fi­ca­tion of new the­ra­peu­tic tar­gets thro­ugh mul­tio­mics (epi­ge­no­mic, trans­crip­to­mic, pro­te­omic, meta­bo­lo­mics, stu­dy­of the micro­bio­me and viro­me, etc.) to assess func­tio­nal cha­rac­te­ri­stics of TME-tumo­ur cell inter­play within the pri­ma­ry tumo­ur and/or meta­sta­ses (e.g the under­ly­ing signa­ling, the trans­crip­tio­nal land­sca­pe, the cell-cell com­mu­ni­ca­tion, the network regu­la­tion of immu­ne cells, etc.), to iden­ti­fy can­di­da­te TME tar­gets and to assess the acti­vi­ty of path­way-tar­ge­ting agents.

1.3 Deve­lop­ment of tools capa­ble of pre­dic­ting tre­at­ment effi­ca­cy and tumo­ur recur­ren­ce using mini­mal­ly- or noni­nva­si­ve tech­ni­qu­es (gene­ra­tion of algo­ri­thms model­ling the network dyna­mics, pre­dic­ti­ve models based on arti­fi­cial intel­li­gen­ce, inte­gra­ting ‑omics data and network appro­aches). Deve­lop­ment of robust noni­nva­si­ve bio­mar­kers of dise­ase cour­se (radio­mics, cell-free cir­cu­la­ting tumo­ur DNA, miR­NA signa­tu­res, cir­cu­la­ting tumo­ur cells, etc.). Sex/gender impact must be con­si­de­red

Aim 2: Tar­ge­ting TME to impro­ve effi­ca­cy of immu­no­the­ra­py in human patients.

2.1 Deve­lop­ment of new pre­ci­sion the­ra­peu­tic stra­te­gies that may pre­vent human tumo­ur recur­ren­ce or resi­stan­ce (T‑cell-based can­cer immu­no­the­ra­pies, immu­ne check­po­int bloc­kers (ICBs), chi­me­ric anti­gen recep­tor (CAR)-T-cells, pre­ven­ti­ve and the­ra­peu­tic vac­ci­nes, etc.).

2.2 Eva­lu­ation in trans­la­tio­nal stu­dies of the impact of TME on tre­at­ment effi­ca­cy and patient out­co­me (cli­ni­cal uti­li­ty of spe­ci­fic TME featu­re detec­tions or iden­ti­fi­ca­tions, cli­ni­cal uti­li­ty of spe­ci­fic intra­tu­mo­ur or peri­phe­ral blo­od immu­ne bio­mar­kers, sex/gender impact, etc.).

2.3 Pha­se I and II cli­ni­cal trials (com­bi­na­tions of ava­ila­ble tre­at­ments, new the­ra­peu­tic stra­te­gies, new admi­ni­stra­tion sche­mes, etc.) tar­ge­ting, or pre­ven­ting resi­stan­ce of mul­ti­ple TME featu­res. Par­ti­cu­lar atten­tion sho­uld be given to gen­der balan­ce inc­lu­sion in order to inter­cept sex/gender dif­fe­ren­ces and to deter­mi­ne if the­re is an asso­cia­tion betwe­en sex/gender and tre­at­ment respon­se.

Szcze­gó­ło­wy opis zakre­su tema­tycz­ne­go kon­kur­su znaj­dą Pań­stwo w doku­men­tach: Call Text i Guide­li­nes for Appli­cants.